724 related articles for article (PubMed ID: 27121691)
1. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
[TBL] [Abstract][Full Text] [Related]
2. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
[TBL] [Abstract][Full Text] [Related]
3. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
4. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
5. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
[TBL] [Abstract][Full Text] [Related]
6. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
8. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?
Michaud L; Burgess A; Huchet V; Lefèvre M; Tassart M; Ohnona J; Kerrou K; Balogova S; Talbot JN; Périé S
J Clin Endocrinol Metab; 2014 Dec; 99(12):4531-6. PubMed ID: 25215560
[TBL] [Abstract][Full Text] [Related]
9. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
10.
Hemrom A; Tupalli A; Alavi A; Kumar R
PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
[TBL] [Abstract][Full Text] [Related]
11. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
Schaarschmidt BM; Gomez B; Buchbender C; Grueneisen J; Nensa F; Sawicki LM; Ruhlmann V; Wetter A; Antoch G; Heusch P
Diagn Interv Radiol; 2017; 23(2):127-132. PubMed ID: 28089955
[TBL] [Abstract][Full Text] [Related]
12. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
13. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
14. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
16. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
17. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial.
Mesguich C; Hulin C; Latrabe V; Asselineau J; Bordenave L; Perez P; Hindie E; Marit G
JMIR Res Protoc; 2020 Sep; 9(9):e17850. PubMed ID: 32909953
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
[TBL] [Abstract][Full Text] [Related]
19. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
[TBL] [Abstract][Full Text] [Related]
20. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
